Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Mary Ford

Internal Medicine Fayetteville, AR Medical Doctor

NPI 1356323042 CMS profile 856947

3344 N Futrall Dr, Fayetteville, AR 72703

Open in the dashboard

General payments

$266

18 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Ford of Fayetteville, AR is reported in the CMS Open Payments database as having received $266 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2023 General $30 2
2022 General $92 6
2021 General $67 5
2020 General $61 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Ford
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mary Ford were reported at $16. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mary Ford Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $61 $119 $33–$402 $114
2021 $67 $135 $37–$521 $132
2022 $92 $141 $42–$496 $149
2023 $30 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $16 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Dexcom, Inc. $93 7 payments
  2. Teva Pharmaceuticals USA, Inc. $60 4 payments
  3. GlaxoSmithKline, LLC. $42 3 payments
  4. AbbVie, Inc. $31 2 payments
  5. Novo Nordisk Inc $23 1 payment
  6. Allergan Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $266 18 payments
Products named General payments · program years 2020–2025
  1. Dexcom G6 Transmitter Endocrinology $82 6 payments
  2. SHINGRIX $42 3 payments
  3. AJOVY $33 2 payments
  4. AirDuo Digihaler $27 2 payments
  5. UBRELVY Neuroscience $16 1 payment
  6. QULIPTA $16 1 payment
  7. UBRELVY Neuroscience $15 1 payment
  8. DEXCOM G6 TRANSMITTER Endocrinology $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

6,470

Median for Internal Medicine: 777

Drug cost

$448,345

Median for Internal Medicine: $73,373

Branded share of claims

19.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 101 $87,638
Ozempic Semaglutide Brand 70 $66,942
Trulicity Dulaglutide Brand 53 $57,622
Mounjaro Tirzepatide Brand 42 $44,057
Januvia Sitagliptin Phosphate Brand 29 $34,851
Xarelto Rivaroxaban Brand 19 $18,694
Tresiba Flextouch U-100 Insulin Degludec Brand 11 $11,250
Farxiga Dapagliflozin Propanediol Brand 21 $10,196
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $7,767
Jardiance Empagliflozin Brand 11 $7,757

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$88,281

Of which drugs: $6,977

Medicare patients

414

Average age 74

Services billed

6,582

330 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 49%
Osteoporosis 38%
Diabetes 22%
Depression 21%
Ischemic heart disease 19%
Chronic kidney disease 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 49 50 $4,012
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 17 $2,597
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 14 1,400 $146

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record